I have been as rattled as anyone by this steep trip back down to these levels, although I did add a little bit in the low 100's and 90's and, for the first time ever, bought some leaps. It is not pleasant when the regulatory oversight with negative implications that Peter dug up comes out of left field. But, long term, I believe in their science, their business model and their pipeline. Hopefully management is talented and smart enough to leverage their SEPR's strategic strengths. As I posted once before, a major challenge is, with the proceeds of the convert added to WC, and the prospect of significant royalties from HMR, J&J, Lilly and others, not to pour capital into what can be the sieve of marketing expense for their own drugs.
I guess another issue, as someone on this thread, I believe, mentioned is the potential change in pharmaceutical companies' way of doing business if the genome segment of the sector takes off and bypasses the need for "therapeutic" drugs, as opposed to gene-altering preventative drugs. Have a good weekend. Regards. Liacos_samui |
